Carl Firth - Aslan Pharmaceuticals Chairman of the Board, CEO
| ASLN Stock | USD 0.54 0.05 10.20% |
Chairman
Mr. Carl Firth was serving as Chief Executive Officer and Director in ASLAN Pharmaceuticals Limited since July 26, 2019. He holds a Bachelor degree in Natural Sciences and a Master degree in Natural Sciences both from University of Cambridge, the United Kingdom, an Executive MBA from London Business School, the United Kingdom, and a Ph.D. in Molecular Biology from University of Cambridge, the United Kingdom. He is also Independent Director in UniBio Science Group Limited, Exploit Technologies Pte Ltd. and Hummingbird Biosciences, as well as Director in Kimba Capital Limited, Liberty Park Music Pte Ltd. and other three companies. He is also a Professor of DukeNUS Graduate Medical School Singapore. since 2019.
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 3 Temasek Avenue, Singapore, Singapore, 039190 |
| Phone | 65 6817 9598 |
| Web | https://aslanpharma.com |
Aslan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6371) % which means that it has lost $0.6371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2664) %, meaning that it created substantial loss on money invested by shareholders. Aslan Pharmaceuticals' management efficiency ratios could be used to measure how well Aslan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -1.89. In addition to that, Return On Capital Employed is likely to grow to -3.61. At this time, Aslan Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 19th of April 2024, Other Current Assets is likely to grow to about 2.8 M, while Net Tangible Assets are likely to drop about 7.1 M.Similar Executives
| Found 12 records | CHAIRMAN Age | ||
| MD MPH | Mineralys Therapeutics Common | 47 | |
| Bruce Harker | Instil Bio | N/A | |
| Ashish Kumar | Inventiva Sa | N/A | |
| Alan Danson | Instil Bio | N/A | |
| Hoyoung Huh | CytomX Therapeutics | 47 | |
| Sean DPHIL | CytomX Therapeutics | 57 | |
| William Ringo | Assembly Biosciences | 71 | |
| Harlan MD | Lyra TherapeuticsInc | 71 | |
| Peter Luo | Adagene | 58 | |
| Sumit Mazumder | Instil Bio | 69 | |
| Joseph Swedish | AN2 Therapeutics | 65 | |
| Joseph Gutnick | Cullinan Oncology LLC | 63 | |
Management Performance
| Return On Equity | -4.27 | ||||
| Return On Asset | -0.64 |
Aslan Pharmaceuticals Leadership Team
Elected by the shareholders, the Aslan Pharmaceuticals' board of directors comprises two types of representatives: Aslan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aslan. The board's role is to monitor Aslan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aslan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aslan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Qingfeng Sun, Independent Director | ||
| Damien Lim, Director | ||
| Abel Ang, Director | ||
| Bertil Lindmark, Chief Medical Officer | ||
| ChinFeng Sun, Independent Director | ||
| Mark McHale, COO | ||
| Charlie Hsu, Investor Director | ||
| ChiChin Wang, IR Director | ||
| Ben Goodger, General Counsel | ||
| Carl Firth, Chairman of the Board, CEO | ||
| Jun Wu, Director | ||
| Meishu Lai, Independent Director | ||
| Zhiyi Xie, Chief Medical Officer | ||
| Alexandre MD, Chief Officer | ||
| Andrew Howden, Independent Director | ||
| Stephen Doyle, Chief Officer | ||
| Kiran Asarpota, Vice President-Finance | ||
| Zhilong Shen, Director | ||
| Robert Hoffman, Independent Director | ||
| Carl EMBA, CEO Founder |
Aslan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aslan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.27 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (3.64) % | ||||
| Current Valuation | 238.89 M | ||||
| Shares Outstanding | 22.63 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Shares Owned By Institutions | 15.48 % | ||||
| Number Of Shares Shorted | 116.78 K | ||||
| Price To Earning | (11.50) X | ||||
| Price To Book | 2.14 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aslan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aslan Pharmaceuticals' short interest history, or implied volatility extrapolated from Aslan Pharmaceuticals options trading.
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.746 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.